Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)
China · Delayed Price · Currency is CNY 18.64
-1.21 (-6.10%)
At close: Jan 27, 2026
SHE:300122 Revenue
Chongqing Zhifei Biological Products had revenue of 2.71B CNY in the quarter ending September 30, 2025, a decrease of -40.19%. This brings the company's revenue in the last twelve months to 10.91B, down -70.05% year-over-year. In the year 2024, Chongqing Zhifei Biological Products had annual revenue of 26.07B, down -50.74%.
Revenue (ttm)
10.91B
Revenue Growth
-70.05%
P/S Ratio
4.09
Revenue / Employee
1.51M
Employees
7,220
Market Cap
44.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.07B | -26.85B | -50.74% |
| Dec 31, 2023 | 52.92B | 14.65B | 38.30% |
| Jan 1, 2023 | 38.26B | 7.61B | 24.83% |
| Dec 31, 2021 | 30.65B | 15.46B | 101.79% |
| Dec 31, 2020 | 15.19B | 4.60B | 43.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.34B |